Brief: AIM ImmunoTech Bolsters Intellectual Property Portfolio For Ampligen With Issuance Of New Netherlands Utility Patent Covering Ampligen And Other AIM Developed dsRNA Products For Use In Covid-19 Treatment Or Prevention
13/06/2022 13:17
June 13 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH BOLSTERS INTELLECTUAL PROPERTY PORTFOLIO
FOR
AMPLIGEN® WITH ISSUANCE OF NEW NETHERLANDS UTILITY PATENT
COVERING AMPLIGEN® AND OTHER AIM DEVELOPED DSRNA PRODUCTS FOR
USE IN COVID-19 TREATMENT OR PREVENTION
Source text for Eikon: ID:nGNE1MWC76
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential